Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

Abstract

Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2. Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2. We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7-82%) for BRCA1 mutation carriers and 74% (7-94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6-65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2. At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2, the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers.

References 32

1. 1.

   Ansquer Y., Gautier C., Fourquet A., Asselain B., Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet. 1998;352(9127):541-541.

   Not in our library10.1016/s0140-6736(05)79248-5

2. 2.

   Antoniou A. C., Gayther S. A., Stratton J. F., Ponder B. A., Easton D. F. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173-190.

   Not in our library10.1002/(sici)1098-2272(200002)18:2<173::aid-gepi6>3.0.co;2-r

3. 3.

   Coleman M., Douglas A., Hermon C., Peto J. Cohort study analysis with a FORTRAN computer program. Int J Epidemiol. 1986;15(1):134-137.

   Not in our library10.1093/ije/15.1.134

4. 4.

   Couch F. J., DeShano M. L., Blackwood M. A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409-1415.

   Not in our library10.1056/nejm199705153362002

5. 5.

   Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265-271.

   Not in our library

6. 6.

   Easton D. F., Steele L., Fields P., Ormiston W., Averill D., Daly P. A., McManus R., Neuhausen S. L., Ford D., Wooster R. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61(1):120-128.

   Not in our library10.1086/513891

7. 7.

   Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343(8899):692-695.

   Not in our library10.1016/s0140-6736(94)91578-4

8. 8.

   Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57(6):1457-1462.

   Not in our library

9. 9.

   Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-689.

   Not in our library10.1086/301749

10. 10.

    Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103-105.

    Not in our library10.1038/ng0197-103

11. 11.

    Gayther S. A., Pharoah P. D., Ponder B. A. The genetics of inherited breast cancer. J Mammary Gland Biol Neoplasia. 1998;3(4):365-376.

    Not in our library10.1023/a:1018779830743

12. 12.

    Gayther S. A., Warren W., Mazoyer S., Russell P. A., Harrington P. A., Chiano M., Seal S., Hamoudi R., van Rensburg E. J., Dunning A. M. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11(4):428-433.

    Not in our library10.1038/ng1295-428

13. 13.

    Hopper J. L., Southey M. C., Dite G. S., Jolley D. J., Giles G. G., McCredie M. R., Easton D. F., Venter D. J. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999;8(9):741-747.

    Not in our library

14. 14.

    Johannesdottir G., Gudmundsson J., Bergthorsson J. T., Arason A., Agnarsson B. A., Eiriksdottir G., Johannsson O. T., Borg A., Ingvarsson S., Easton D. F. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996;56(16):3663-3665.

    Not in our library

15. 15.

    Krainer M., Silva-Arrieta S., FitzGerald M. G., Shimada A., Ishioka C., Kanamaru R., MacDonald D. J., Unsal H., Finkelstein D. M., Bowcock A. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997;336(20):1416-1421.

    Not in our library10.1056/nejm199705153362003

16. 16.

    Langston A. A., Malone K. E., Thompson J. D., Daling J. R., Ostrander E. A. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334(3):137-142.

    Not in our library10.1056/nejm199601183340301

17. 17.

    Malone K. E., Daling J. R., Thompson J. D., O'Brien C. A., Francisco L. V., Ostrander E. A. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998;279(12):922-929.

    Not in our library10.1001/jama.279.12.922

18. 18.

    Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.

    Not in our library10.1126/science.7545954

19. 19.

    Neuhausen S., Gilewski T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996;13(1):126-128.

    Not in our library10.1038/ng0596-126

20. 20.

    Newman B., Mu H., Butler L. M., Millikan R. C., Moorman P. G., King M. C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279(12):915-921.

    Not in our library10.1001/jama.279.12.915

21. 21.

    Nordling M., Karlsson P., Wahlström J., Engwall Y., Wallgren A., Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res. 1998;58(7):1372-1375.

    Not in our library

22. 22.

    Offit K., Gilewski T., McGuire P., Schluger A., Hampel H., Brown K., Swensen J., Neuhausen S., Skolnick M., Norton L. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347(9016):1643-1645.

    Not in our library10.1016/s0140-6736(96)91484-1

23. 23.

    Peto J., Collins N., Barfoot R., Seal S., Warren W., Rahman N., Easton D. F., Evans C., Deacon J., Stratton M. R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943-949.

    Not in our library10.1093/jnci/91.11.943

24. 24.

    Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997;17(3):341-345.

    Not in our library10.1038/ng1197-341

25. 25.

    Smith T. M., Lee M. K., Szabo C. I., Jerome N., McEuen M., Taylor M., Hood L., King M. C. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res. 1996;6(11):1029-1049.

    Not in our library10.1101/gr.6.11.1029

26. 26.

    Struewing J. P., Abeliovich D., Peretz T., Avishai N., Kaback M. M., Collins F. S., Brody L. C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11(2):198-200.

    Not in our library10.1038/ng1095-198

27. 27.

    Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-1408.

    Not in our library10.1056/nejm199705153362001

28. 28.

    Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjörd J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079-1084.

    Not in our library

29. 29.

    Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjörd J. E. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998;352(9137):1337-1339.

    Not in our library10.1016/s0140-6736(98)03300-5

30. 30.

    Verhoog L. C., Brekelmans C. T., Seynaeve C., van den Bosch L. M., Dahmen G., van Geel A. N., Tilanus-Linthorst M. M., Bartels C. C., Wagner A., van den Ouweland A. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351(9099):316-321.

    Not in our library10.1016/s0140-6736(97)07065-7

31. 31.

    Watson P., Marcus J. N., Lynch H. T. Prognosis of BRCA1 hereditary breast cancer. Lancet. 1998;351(9099):304-305.

    Not in our library10.1016/s0140-6736(98)22005-8

32. 32.

    Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792.

    Not in our library10.1038/378789a0

Cited by papers we hold 14

• Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers · 2022
  Not checked
• Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients · 2022
  Not checked
• Advanced Approaches to Breast Cancer Classification and Diagnosis · 2021
  No notice
• Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis · 2020
  No notice
• Development and Validation of Nomograms for Predicting Overall and Breast Cancer–Specific Survival in Young Women with Breast Cancer: A Population-Based Study · 2018
  Not checked
• Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study · 2018
  No notice
• Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants · 2018
  No notice
• Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures · 2018
  No notice
• Interplay between Fanconi anemia and homologous recombination pathways in genome integrity · 2016
  No notice
• Lobular breast cancer: incidence and genetic and non-genetic risk factors · 2015
  No notice
• Triple negative breast cancer: looking for the missing link between biology and treatments · 2015
  No notice
• The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions · 2008
  Corrected
• Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family · 2004
  No notice
• A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes · 2002
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.